CYCLOPE BIO SL

CYCLOPE BIO SL specializes in the synthesis and procurement of enantiomerically pure organic intermediates for biomedical research, with demonstrated expertise in chiral chemistry and the production of stereochemically defined diamine compounds such as cyclopentane diamine and tetrahydrofuran diamine. The company’s core capabilities center on advanced organic synthesis, enantioselective catalysis, and the scalable manufacturing of high-purity, non-racemic building blocks critical to pharmaceutical development. Their technical focus includes precision control of stereochemistry, purification of sensitive amine derivatives, and adherence to Good Manufacturing Practices for research-grade chemical supply. This specialization enables support for drug discovery programs requiring enantiopure scaffolds to study biological target specificity and metabolic stability. The contractor has delivered specialized chemical procurement services to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the Department of Health and Human Services. This engagement reflects a focused relationship with NIH-funded research entities seeking high-purity, structurally defined organic compounds for mechanistic studies in metabolic and neurological disease models. The nature of the award suggests a contract model centered on severable, demand-driven acquisition of research chemicals rather than long-term development partnerships. The primary NAICS code, 325199, indicates activity in the manufacturing of other basic organic chemicals, specifically non-pharmaceutical-grade but biologically relevant intermediates used in preclinical research. This positions CYCLOPE BIO SL within the niche segment of chemical supply for academic and government-funded life sciences research, distinct from bulk commodity chemical producers. The entity operates as an X6 structure from Llanera, with no publicly disclosed federal certifications. Its market presence is narrowly defined by its capacity to produce and deliver specialized chiral amines, serving a highly technical, low-volume segment of the federal biomedical research supply chain.